XML 31 R53.htm IDEA: XBRL DOCUMENT
v3.19.3.a.u2

Collaboration and Other Agreements, Provention (Details) $ / shares in Units, $ in Thousands | 1 Months Ended | 3 Months Ended | 12 Months Ended
--- | --- | --- | ---
May 31, 2018 USD ($) performance_obligation $ / shares shares | Dec. 31, 2019 USD ($) | Sep. 30, 2019 USD ($) | Jun. 30, 2019 USD ($) | Mar. 31, 2019 USD ($) | Dec. 31, 2018 USD ($) | Sep. 30, 2018 USD ($) | Jun. 30, 2018 USD ($) | Mar. 31, 2018 USD ($) | Dec. 31, 2019 USD ($) | Dec. 31, 2018 USD ($) | Dec. 31, 2017 USD ($)
Collaboration and Other Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  | $ 25,192 | $ 18,741 | $ 10,593 | $ 9,662 | $ 15,794 | $ 20,798 | $ 18,834 | $ 4,695 | $ 64,188 | $ 60,121 | $ 157,742
Deferred revenue |  | 10,700 |  |  |  | 21,721 |  |  |  | 10,700 | 21,721 |
Deferred revenue included in long-term liabilities |  | 9,153 |  |  |  | 19,001 |  |  |  | 9,153 | 19,001 |
Provention Bio, Inc. (Provention) |  |  |  |  |  |  |  |  |  |  |  |
Collaboration and Other Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Number of performance obligations | performance_obligation | 2 |  |  |  |  |  |  |  |  |  |  |
Transaction price | $ 6,100 |  |  |  |  |  |  |  |  |  |  |
Stock warrants (in shares) | shares | 2,432,688 |  |  |  |  |  |  |  |  |  |  |
Green Cross |  |  |  |  |  |  |  |  |  |  |  |
Collaboration and Other Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  | $ 1,900 |  |  |  |  | $ 1,900 |
Deferred revenue included in long-term liabilities |  | $ 20,100 |  |  |  |  |  |  |  | $ 20,100 |  |
Provention License Agreement | Provention PRV3279 | Provention Bio, Inc. (Provention) |  |  |  |  |  |  |  |  |  |  |  |
Collaboration and Other Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Consideration received common stock warrant exercise price (in usd per share) | $ / shares | $ 2.50 |  |  |  |  |  |  |  |  |  |  |
Potential development and regulatory milestone payments | $ 65,000 |  |  |  |  |  |  |  |  |  |  |
Potential commercial milestone payments | $ 225,000 |  |  |  |  |  |  |  |  |  |  |
Asset Purchase Agreement | Provention PRV031 | Provention Bio, Inc. (Provention) |  |  |  |  |  |  |  |  |  |  |  |
Collaboration and Other Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Consideration received common stock warrant exercise price (in usd per share) | $ / shares | $ 2.50 |  |  |  |  |  |  |  |  |  |  |
Potential development and regulatory milestone payments | $ 170,000 |  |  |  |  |  |  |  |  |  |  |
Potential commercial milestone payments | 225,000 |  |  |  |  |  |  |  |  |  |  |
Potential milestone payment to third parties for intellectual property under agreement | 1,300 |  |  |  |  |  |  |  |  |  |  |
Revenues From License Agreements | Provention Bio, Inc. (Provention) |  |  |  |  |  |  |  |  |  |  |  |
Collaboration and Other Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Revenues | $ 6,100 |  |  |  |  |  |  |  |  |  |  |

X
- Definition Collaborative Agreement Consideration Received Common Stock Warrant Exercise Price Per Share + References No definition available. + Details
Name: | mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare
Namespace Prefix: | mgnx_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative Agreement Consideration Received Common Stock Warrants Number Of Shares + References No definition available. + Details
Name: | mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares
Namespace Prefix: | mgnx_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Collaborative Agreement Transaction Price + References No definition available. + Details
Name: | mgnx_CollaborativeAgreementTransactionPrice
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Number Of Performance Obligations + References No definition available. + Details
Name: | mgnx_NumberOfPerformanceObligations
Namespace Prefix: | mgnx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Potential Commercial Milestone Payments Under Agreement + References No definition available. + Details
Name: | mgnx_PotentialCommercialMilestonePaymentsUnderAgreement
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Potential Development and Regulatory Milestone Payments Under Agreement + References No definition available. + Details
Name: | mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Potential Milestone Payment To Third Parties For Intellectual Property Under Agreement + References No definition available. + Details
Name: | mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(5)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_DeferredRevenueCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(5)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_DeferredRevenueNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=mgnx_ProventionBioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=mgnx_GreenCrossCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=mgnx_ProventionLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ProventionPRV3279Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=mgnx_AssetPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ProventionPRV031Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |